Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression data from patients with colorectal cancer

ABSTRACT: Microarray analyses for the identification of differences in gene expression patterns have increased our understanding of the molecular genetic events in colorectal cancer. We used gene expression analysis data from recurrent and non-recurrent patients with colorectal cancer to identify differentially expressed probes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE64857 | GEO | 2015/02/23

SECONDARY ACCESSION(S): PRJNA272413

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression data from patients with colorectal cancer

Project description:Microarray analyses for the identification of differences in gene expression patterns have increased our understanding of the molecular genetic events in colorectal cancer. We used gene expression analysis data from recurrent and non-recurrent patients with colorectal cancer to identify differentially expressed probes. Tumor tissues were taken from 81 patients with colorectal cancer, rapidly frozen in RNAlater, and isolated using Trizol. Gene expression pro?les were determined using Affymetrix HG-U133 Plus 2.0 GeneChips.We aimed to identify a molecular signature that can reliably identify colorectal cancer patients at high risk for recurrence.

2015-02-23 | E-GEOD-64857 | biostudies-arrayexpress

Downregulation of three tumour suppressor genes SLC26A3, DCN and TPM1 in colorectal cancer

2009-11-01 | GSE14010 | GEO

Downregulation of three tumour suppressor genes SLC26A3, DCN and TPM1 in colorectal cancer

Project description:Despite identification of major genes and pathways involved in development of colorectal cancer (CRC) it became obvious that several steps in these pathways might be bypassed by other yet unknown genetic events that lead towards CRC. To improve our understanding of the genetic mechanisms of CRC development we used microarrays to identify novel genes involved in development of CRC. In order to identify possible novel genes involved in the development of colorectal cancer we analysed the expression profile of 16 colorectal cancers. We used dual color approach. Tumour tissue was labeled with Cy5 and corresponding normal tissue was labeled with Cy3. Each array contained at least 4 replicate spots for each gene analysed. Expression was obtained by calculating median from replicate spots. Genes not present in at least 100% of all samples were filtered out. Median value for each gene from 16 arrays was calculated.

2010-06-20 | E-GEOD-14010 | biostudies-arrayexpress

Single cell 3' RNA sequencing of 23 Korean colorectal cancer patients

Project description:For the understanding intrinsic cancer cell signatures and the surrounding microenviroment, we provide single-cell 3' RNA sequencing dataon 63,689 cells from 23 CRC patients with 23 primary colorectal cancer and 10 matched normal mucosa samples. Analysis of primary colorectal cancer and normal mucosa samples depicts a comprehensive cellular landscape of colorectal cancer and potential cellular interaction, which would be a valuable resource for the development of therapeutic strategies.

2020-04-04 | GSE132465 | GEO

Circulating microRNA of advanced colorectal cancer patients

Project description:Recent advances in high-throughput technologies have provided an unprecedented opportunity to identify molecular markers of disease processes. This plethora of complex -omics data has simultaneously complicated the problem of extracting meaningful molecular signatures and opened up new opportunities for more sophisticated integrative and holistic approaches. In this era, effective integration of data-driven and knowledge-based approaches for biomarker identification has been recognised as key to improving the identification of high-performance biomarkers, and necessary for translational applications. Here, we have evaluated the role of circulating microRNA as a means of predicting the prognosis of patients with colorectal cancer, which is the second leading cause of cancer-related death worldwide. We have developed an innovative multi-objective optimisation method which effectively integrates a data-driven approach with the knowledge obtained from the microRNA-mediated regulatory network to identify robust plasma microRNA signatures which are reliable in terms of predictive power as well as functional relevance. We have found 9 signatures of colorectal cancer prognosis comprising a total of 19 circulating microRNAs. The identified signatures predict the patients’ survival outcome and target pathways underlying colorectal cancer progression. The altered expression of the microRNAs within these signatures was confirmed in two independent public datasets of plasma and tumour samples of patients in early stage versus advanced colorectal cancer.

2018-04-12 | GSE112955 | GEO

Understanding the progression of metastatic colorectal cancer

Project description:Understanding the progression of metastatic colorectal cancer

| PRJNA498172 | ENA

Understanding the progression of metastatic colorectal cancer

Project description:Understanding the progression of metastatic colorectal cancer

| PRJNA498173 | ENA

Cell-of-origin epigenetic signatures are maintained during colorectal carcinogenesis

Project description:Colorectal adenomas are precursor lesions of colorectal cancers and represent clonal amplifications of single cells from colonic crypts. DNA methylation patterns specify cell-type identity during cellular differentiation and therefore provide novel opportunities for the molecular analysis of tumors. We have now analyzed DNA methylation patterns in colorectal adenomas and identified three biologically defined subclasses that describe different intestinal crypt differentiation stages. Importantly, colorectal carcinomas could be classified into the same methylation subtypes, reflecting their shared cell-types of origin with adenomas. Further data analysis also revealed significantly reduced overall survival for one of the subtypes. Our results establish a novel concept for understanding the methylation patterns observed in colorectal cancer and provide opportunities for tumor subclassification and patient stratification.

2018-06-12 | E-MTAB-6450 | biostudies-arrayexpress

Tissue and blood microRNA array profiles of colorectal cancer patients

Project description:microRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs offer great potential as cancer biomarkers. The objective of the study was to correlate the differential expression of miRNAs in tissue and blood in the identification of biomarkers for early detection of colorectal cancer (CRC).

2013-12-30 | GSE39845 | GEO

Hi-ChIP dataset for epigenomics landscape of colorectal cancer

Project description:Enhancer aberrations are beginning to emerge as a key feature of colorectal cancers, however, we have limited understanding of epigenomic patterns that distinguish tumors and underlying heterogeneity between tumors. Here, using epigenomic profiling of colorectal tumors, adenomas and normal colon tissues, we identify unique pattern of regulatory elements in colorectal cancer, which could reliably distinguish tumors from normal colon specimens. We define shared and unique enhancer elements during colorectal cancer progression using normal adjacent colon, adenomas and adenocarcinomas. We validate the functional nature of tumor-specific enhancers for important oncogenes such as ASCL2 and Fzd10. NMF clustering identified 4 epigenetic (EPIC) subtypes in colorectal cancer, which mimics consensus molecular subtypes (CMS)1, with an advantage of introducing a novel epigenetically-identifiable subtype with poor prognosis and survival. Based on this correlation, we defined and validated a combination therapeutic strategy of enhancer-blocking BETi with pathway specific inhibitor for 3 CMS subtypes. In conclusion, by comprehensive characterization of chromatin state patterns in colorectal tumors, we define epigenomic patterns during tumor evolution, heterogeneity of enhancers among patients and a combination therapy strategy for CMS-subgroups.

2021-05-22 | GSE136629 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data